Mozafancogene Autotemcel

Taylor Tieden for BioSpace On the FDA’s docket this month are two decisions pushed back from 2025, including one for a rare form of obesity and another for dry eye disease. The FDA will decide on five major drug applications this month, two of which had their reviews delayed from last year. Also lined up are two big pharma verdicts: one for a label expansion and another for a rare liver disease. Read below for more. BMS Plots Arthritis Expansion for Sotyktu Bristol Myers Squibb is looking to add psoriatic arthritis to the label of oral drug Sotyktu, opening its use in adults with active disease. The FDA’s decision is expected by March 6. The pharma is supporting the expansion bid with data from the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 studies. A readout from the latter study in March 2025 showed that 54.2% of patients on Sotyktu achieved at least a 20% improvement in symptoms, as compared with 39.4% of placebo comparators after 16 weeks, a statistically significant advantage for BMS’ drug. Similarly, POETYK PsA-1 data released in October 2025 showed a significantly higher percentage of patients saw a 20% improvement in symptoms versus placebo. Sotyktu is an oral tyrosine kinase inhibitor that suppresses the inflammatory cascade. The drug was first approved in September 2022 for moderate-to-severe plaque psoriasis. Aldeyra Hopes Third Time’s the Charm for Dry Eye Disease Drug By March 16, the FDA is expected to release a decision on Aldeyra Therapeutics’ RASP modulator reproxalap, which the biotech is proposing for the treatment of dry eye disease. Reproxalap has had a difficult regulatory run so far. In November 2023, the drug received its first rejection , with the FDA at the time arguing that Aldeyra had failed to sufficiently establish efficacy for ocular symptoms in dry eye disease. Reproxalap was again rejected in April last year, similarly due to questions over efficacy. Aldeyra filed a resubmission in June 2025—which the FDA accepted in July —including additional data from a dry eye chamber study , which in May last year showed significantly improved ocular discomfort versus vehicle. The target action date for reproxalap’s third trip to the FDA was originally Dec. 16, but that was pushed back three months to allow for a review of additional submissions. Rhythm Waits Out Delay for Rare Obesity Drug Like Aldeyra, Rhythm Pharmaceuticals is riding out a regulatory delay for its melanocortin 4 receptor (MC4R) agonist Imcivree, being proposed for the treatment of acquired hypothalamic obesity. The FDA is set to release a decision on or before March 20. Imcivree’s application is supported by data from the Phase 3 TRANSCEND trial, which found that the drug cut body mass index by 19.8% versus placebo at 52 weeks. The FDA accepted Imcivree’s data package in August last year and originally set a target action date of Dec. 20 but delayed the decision by three months after the biotech filed additional sensitivity data. Imcivree’s first approval came in November 2020 to help manage weight in patients with obesity due to POMC, PCSK1 or LEPR deficiency. Acquired hypothalamic obesity is a rare form of chronic weight-gain linked to physical damage to, or anatomical abnormalities of the hypothalamus. Dysregulated MC4R signaling is a key pathway in this condition, leading to uncontrolled hunger and weight-gain. GSK Gears Up For Decision in Rare Autoimmune Liver Disease By March 24, the FDA will release a decision for GSK’s linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC). Available orally, linerixibat is a targeted blocker of the ileal bile acid transporter, which inhibits the reuptake of bile acid, in turn lowering the levels of several itch mediators across the body. Data from the Phase 3 GLISTEN study, released in May last year , showed that linerixibat significantly improved monthly itch scores versus placebo, while also acing key secondary endpoints such as sleep interference and the speed at which itch was eased. PBC is a liver disease characterized by the disrupted flow of bile from the liver, leading to excessive bile levels in circulation. The condition can then give rise to cholestatic pruritus, or an internal itch that cannot be addressed by scratching, according to GSK. Rocket Gives Kresladi Another Try To close off the month, the FDA on or before March 28 will release a decision on Rocket Pharmaceuticals’ proposal to use the gene therapy Kresladi for leukocyte adhesion deficiency-I (LAD-I). Delivered using an adeno-associated virus vector, Kresladi provides patients with a functioning copy of the ITGB2 gene, which in turn can encode a key surface protein on immune cells. This protein is otherwise dysfunctional in LAD-I , leading to a compromised immune response that makes patients susceptible to recurrent and severe infections. There are around 300 LAD-I cases worldwide. Pivotal Phase 1/2 data showed a 100% overall survival rate at 12 months after Kresladi treatment. The FDA in June 2024 rejected Rocket’s application, though the rebuff was due to issues with chemistry, manufacturing and controls. The biotech refiled its approval package mid-2025, which the FDA accepted in October. Gene therapy Rocket Aborts FDA Filing for Rare Blood Disease Gene Therapy Rocket Pharmaceuticals’ strategic realignment initiative in July pulled funding from fanca-cel, which the biotech was developing for Fanconi anemia. October 6, 2025 · 2 min read · Tristan Manalac Read more

除了通过黑夜的道路，人们不能到达黎明。——纪伯伦 这是本老哥新年第一股深度分析，欢迎读者们进来交流讨论。 一 公司简介 火箭制药是一家专注于开发罕见病基因疗法的临床阶段生物技术公司。公司建立了双重的技术平台：一是基于慢病毒的体外基因疗法平台，主要用于治疗血液系统罕见病；二是基于腺相关病毒的体内基因疗法平台，主要用于治疗心脏及神经肌肉疾病。 二 核心管线进展 1. 达农病基因疗法 (RP-A501) 达农病是一种由 LAMP2基因突变引起的X连锁显性遗传病。该突变导致细胞自噬过程受损，糖原和自噬体在心脏、肌肉等组织中异常堆积，从而引发严重且进展迅速的心肌病、骨骼肌无力及智力障碍。男性患者病情尤为凶险，常于青春期或成年早期因心力衰竭死亡，目前除心脏移植外无有效疗法。据公司估计，欧美市场的患者规模约为 15000至30000人。 该管线的关键进展在于其AAV9载体基因疗法RP-A501。该疗法在2025年经历了一次临床暂停挫折，因一位受试者患毛细血管渗漏综合征死亡，但不到3个月之内，公司与FDA达成一致，临床搁置被解除。 公司以调整后的方案（采用3.8 × 10¹³ GC/kg的剂量）重新开始患者给药。此前，基于积极的I期临床数据，该疗法已获得FDA授予的再生医学先进疗法资格，数据显示其能有效修复LAMP2蛋白表达，并在心脏结构和功能等多个终点上表现出持久的改善或稳定。FDA也已认可其采用自然史对照的单臂II期关键试验设计，为其潜在的加速批准路径奠定了基础。 2. 白细胞粘附缺陷症I型基因疗法 (KRESLADI) 白细胞粘附缺陷症I型是一种由 ITGB2基因突变 导致CD18整合素缺陷的罕见常染色体隐性遗传病。该缺陷使得患者白细胞无法迁移至感染部位，导致出生后即出现危及生命的反复严重感染、伤口难以愈合及脐带脱落延迟。重度患者若不接受成功的造血干细胞移植，死亡率极高。该疾病极为罕见，全球报告病例约300例，发病率约为百万分之一。 其核心疗法KRESLADI™是一种离体慢病毒基因疗法，目前已进入上市审批的最后阶段。其生物制品许可申请已重新获FDA受理并授予优先审评资格，最终的PDUFA目标日期定为2026年3月28日。该申请基于一项全球I/II期临床试验的积极数据，结果显示其实现了100%的总体生存率并具有持久的疗效，有望成为该疾病除造血干细胞移植外的突破性治疗选择。 3. 其他重要在研管线 公司管线还包括：针对范可尼贫血的慢病毒基因疗法RP-L102，它已获得FDA的再生医学先进疗法和罕见儿科疾病认定；针对PKP2致心律失常性心肌病的AAV基因疗法RP-A601，正处于关键试验设计讨论阶段；以及针对BAG3相关扩张型心肌病的AAV基因疗法RP-A701，其I期临床试验已经启动。 三 投资观点总结 1 拥有明确的关键催化剂：即2026年上半年RP-A501试验的重新给药，以及2026年3月28日KRESLADI™的审批决议。 2 其慢病毒与AAV双技术平台均已获得强大的临床概念验证和FDA的认可，且针对超罕见病领域，竞争格局良好，市场独占性潜力高。 3 公司已处于商业化前夜，2项核心基因疗法将在几年内带来数亿美元的销售收入，且现金充足，可支持业务到2028年3季度。 4 安全事件、股东诉讼本是新药研发过程的常态现象，何况已经得到解决。但市场毫不留情让股价相比历史高点缩水95%，这正好给了逆势而行者大好时机。 四 主要风险 包括基因疗法的长期安全性、公司的生产与商业化能力、达农病最终疗效数据的验证，以及高昂治疗费用可能面临的支付挑战。 五 结论 1 综合考虑基本面，当前股价3.46/股，3.74亿美元市值显著被低估，分析师给出的目标均价在10美元以上，2-3倍的空间为投资人提供了充足的安全边际。 2 股价有望缓步向上迎接3月28日之前的审批决议，这也是公司价值重估的关键一跃。 $Solid Biosciences(SLDB)$ $Sangamo Therapeutics Inc(SGMO)$ $Sana Biotechnology, Inc.(SANA)$ $Intellia Therapeutics Inc(NTLA)$ $Rocket Pharmaceuticals, Inc.(RCKT)$